Utility of FDG-PET scanning in lymphoma by WHO classification

• Published in: Blood Vol. 101; no. 10; pp. 3875 - 3876
• Main Authors: Elstrom, Rebecca, Guan, Liang, Baker, Gary, Nakhoda, Khozaim, Vergilio, Jo-Anne, Zhuang, Hongming, Pitsilos, Stephanie, Bagg, Adam, Downs, Lisa, Mehrotra, Amit, Kim, Scott, Alavi, Abass, Schuster, Stephen J.
• Format: Journal Article
• Language: English
• Published: Washington, DC Elsevier Inc 15-05-2003; The Americain Society of Hematology
• Subjects: Biological and medical sciences; Fluorodeoxyglucose F18; Hematologic and hematopoietic diseases; Humans; Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis; Lymphoma, Non-Hodgkin - classification; Lymphoma, Non-Hodgkin - diagnostic imaging; Medical sciences; Radiopharmaceuticals - therapeutic use; Recurrence; Reproducibility of Results; Sensitivity and Specificity; Tomography, Emission-Computed; Radionuclide study; Human; Lymphoproliferative syndrome; Stage classification; Classification; Exploration; Malignant hemopathy; Single photon emission tomography; Lymphoma
• ISSN: 0006-4971; 1528-0020
• DOI: 10.1182/blood-2002-09-2778

We retrospectively evaluated 18fluoro-2-deoxyglucose positron emission tomography (FDG-PET) scans in 172 patients with lymphoma and correlated results with pathologic diagnosis using the World Health Organization (WHO) classification system. In total, FDG-PET detected disease in at least one site in 161 patients (94%) and failed to detect disease in 11 patients (6%). The most frequent lymphoma diagnoses were diffuse large B-cell lymphoma (LBCL; n = 51), Hodgkin lymphoma (HL; n = 47), follicular lymphoma (FL; n = 42), marginal zone lymphoma (MZL; n = 12), mantle cell lymphoma (MCL; n = 7), and peripheral T-cell lymphoma (PTCL; n = 5). FDG-PET detected disease in 100% of patients with LBCL and MCL and in 98% of patients with HL and FL. In contrast, FDG-PET detected disease in only 67% of MZL and 40% of PTCL. Comparison with bone marrow biopsies showed that FDG-PET was not reliable for detection of bone marrow involvement in any lymphoma subtype.